Study of somatostatin on enhancing chemosensitivity of carcinoma of gdllbladder cells in vitro

Abstract

Abstract: AIM: To explore the change of chemosensitivity of carcinoma of gdllbladder cells after treated with somatostatin.METHODS: Twenty-four hours after somatostatin given, gradient concentrations of Adriamycin were added and growth curve of carcinoma of gdllbladder cells was investigated.The inhibitory effects of Adriamycin plus somatostatin and adriamycin alone were compared .RESULTS: Concentration-dependent inhibition of cell growth was shown in carcinoma of gdllbladder cells in adriamycin group (P<0.01).Somatostatin was found to induce carcinoma of gdllbladder cells growth arrest in DNA-Synthesis phrase, i.e., S phrase.After treated with somatostatin, inhibition of adriamycin was enhanced compared with that in adriamycin alone group (P<0.01).CONCLUSION: Somatostatin can enhance the chemosensitivity of carcinoma of gdllbladder cells treating with adriamycin.

Key words: somatostatin, adriamycin, chemosensitivity, carcinoma of gdllbladder cells

CLC Number:

R965
R979.1

LI Ji-Yu, QUAN Zhi-Wei, ZHANG Qiang, LIU Jian-Wen. Study of somatostatin on enhancing chemosensitivity of carcinoma of gdllbladder cells in vitro[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2004, 9(2): 171-176.

[1]	LIN Xueyan, LIN Zhihui, HUANG Huping. Effect of terlipressin on renal function in cirrhotic patients with esophageal gastric varices bleeding and normal baseline renal function [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(7): 775-784.
[2]	JIN Le, JIANG Duochen, CHEN Hongxiao, LIU Su, CHEN Zhaolin, JU Jing. Quercetin reverses adriamycin resistance by activating GSK-3β/β-catenin pathways through GAS5 in breast cancer cells [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(12): 1344-1351.
[3]	PAN Zhanhe, WANG Xin, SU An, ZHANG Peng, JI Haonan, WANG Xiaomei. Mechanism of celecoxib reverses adriamycin resistance in NK/T cell lymphoma cells by Notch 1/NF-κB/STAT3 pathway [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(12): 1330-1336.
[4]	CHENG Yuan-guang, WU Pei. Expression of somatostatin receptor type 2 in colorectal cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(10): 1100-1104.
[5]	SHEN Qun-shan, HUANG Hou-bao, PAN Cai-ming, XUE Jun, CAI Zhang-yu, WANG Xiao, JIANG Shu-chuan. Prevention effect of 4-HPR on bladder tumor in SD rats: An in vivo experiment [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2012, 17(9): 972-977.
[6]	HU Guang-Long, ZHAO Guo-Hai. Expression of ENA-78 in rats with severe acute pancreatitis and roles of somatostatin treatment [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2012, 17(8): 868-873.
[7]	YANG Yan-lang^1,2, ZOU He-qun¹, ZHANG Dao-you², WANG Yu-wei², LI Fan-xia², GAO Chao-qing², XU Hai-hong², CHENG Xiao-mei². Renal tubular protection effect of combining benazepril and spironolactone in adriamycin-induced nephritic rats [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2012, 17(4): 381-386.
[8]	ZHAO Wen-ying, CHEN Dong-yun, XING Wen, WU Ming , YANG Zhi-min, JI Zhao-ning. Primary exploration on the protective effect of phosphocreatine sodium on adriamycin-induced cardiotoxicity in mice [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2011, 16(3): 259-262.
[9]	XU Xiao-bing, ZHANG Xiao-hua, YANG Miao-fang, WU Xiao-wei, LI Min-li, ZHU Ren- min. Phosphotyrosine phosphatase eta mediates somatostatin's inhibition of hepatocellular carcinoma cell proliferation [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2011, 16(11): 1222-1226.
[10]	WANG Jie-sheng, WANG Qin-xian, CHEN Fu-xin, LI Hong-chun, LUO Ke-xue. Somatostatin-induced hyperglycemia in case of diabetes and pharmacology analysis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2011, 16(11): 1260-1263.
[11]	CHEN Ji-hong, ZHOU Dong, GAO Kun, HE Wei-ming,WANG Yue-juan, SUN Wei. Expression of NF-κB and IκB in rats with adriamycin nephropathy and the role of Dahuangzhechong Wan [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2011, 16(1): 22-26.
[12]	LIU Yi-ming, LIN Ai-hua, DENG Shi-gui, WU Zhi-feng, OU Run-mei. Tissue distribution of adriamycin-loaded chitosan nanoparticles surface-modified with glycyrrhizin in mice [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2010, 15(1): 66-71.
[13]	YANG Yan-lang, ZHANG Dao-you, WANG Xiang-ming, CUI Ming-chun, WU Xiao-dong. Renoprotective effect and mechanisms of benazepril and pentifylline on adriamycin nephropathy rats [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2009, 14(7): 736-740.
[14]	XU Xiao-bing, YANG Miao-fang, ZHU Ren-min. Advancement on the therapy of somatostatin on liver fibrosis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2009, 14(6): 707-710.
[15]	YAO Rong-xin, FENG Liang-hua, XIA Yi-zi, ZHU Bao-ling. Study on protection and mechanism for adriamycin-induced cardiotoxicity with tiopronin in rats [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2009, 14(11): 1216-1220.

Study of somatostatin on enhancing chemosensitivity of carcinoma of gdllbladder cells in vitro

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments